Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN901), with a maytansinoid cell-killing agent, DM1, attached using a disulfide linker, SPP. (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine.)[citation needed]
Lorvotuzumab mertansine is an experimental agent created for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer).[1][2]
It has been granted Orphan drug status for Merkel cell carcinoma.[3]
It has reported encouraging Phase II results for small-cell lung cancer.[4]
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 3.12.36.72